US Capitol Capsule: Biopharma weighs in on US-EU trade pact
This article was originally published in Scrip
Executive Summary
Negotiations set to soon start between the US and the EU aimed at enhancing their trade and investment relationships should be comprehensive and ambitious – addressing not only regulatory compatibility initiatives, but also intellectual property (IP) protections, market access provisions and customs, tariffs and public procurement measures, advised the Pharmaceutical Research and Manufacturers of America (PhRMA).